A new study identified key factors that can impact the long-term weight loss of patients with obesity who were prescribed injectable semaglutide or liraglutide for the treatment of type 2 diabetes or ...

A new study finds that weight loss drugs Like Ozempic could trigger bone loss. Doctors explain why, and how to protect ...

Injectable prescription drugs that reduce appetite — like Ozempic, Saxenda and Mounjaro — have skyrocketed in popularity in ...

The median time receiving treatment was 3.9 months. The researchers found that GLP-1 RA use was associated with a lower rate of any hyperkalemia and moderate-to-severe hyperkalemia compared with ...

Also, we see that, for instance, with certain individuals, when they take GLP-1 RA therapy, they might have a lot of gastrointestinal side effects. One challenge we have in the addiction field is that ...

The study concentrates on the FDA-approved injectable medications semaglutide and liraglutide. A study conducted by the ...

Some people lose more weight on drugs like Ozempic, Wegovy and Saxenda than others, and a new study reveals why that might be.

This change is so pronounced that some bariatric surgery programs have closed. This trend is not just about GLP-1 medications, however. It represents a broader transformation in how the country and ...

A Cleveland Clinic study identified key factors that can impact the long-term weight loss of patients with obesity who were ...

Key factors that impact long-term weight loss in patients prescribed GLP-1 RA medications." ScienceDaily. ScienceDaily, 13 September 2024. <www.sciencedaily.com Semaglutide, a medication initially ...